Neha Mathur, MD
Gastroenterology · Houston, TXNPI 1821254483
Payments from drug & device makers
Across 494 payments — averaging $178.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$39K
- Regeneron Healthcare Solutions, Inc.$26K
- Ardelyx, Inc.$15K
- AbbVie$4K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$826
- plus $3K from 25 others
What the payments were for
- Consulting fees$2,9153%
- Speaking & faculty fees$63,39972%
- Travel & lodging$11,00112%
- Food & beverage$10,96212%
- Education$1220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 29 | $38,695 |
| Regeneron Healthcare Solutions, Inc. | 30 | $25,845 |
| Ardelyx, Inc. | 24 | $14,971 |
| AbbVie(2 entities) | 185 | $3,621 |
| Johnson & Johnson | 83 | $1,471 |
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $826 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $363 |
| Lilly USA, LLC | 5 | $324 |
| Bristol Myers Squibb | 11 | $252 |
| Pfizer | 9 | $246 |
| Ferring Pharmaceuticals Inc. | 4 | $224 |
| Pharmacosmos Therapeutics Inc. | 6 | $170 |
| Neuraxis, Inc. | 3 | $161 |
| Phathom Pharmaceuticals, Inc. | 3 | $159 |
| Histosonics, Inc. | 1 | $150 |
| Conmed Corporation | 1 | $128 |
| Celltrion USA Inc. | 7 | $126 |
| Ironwood Pharmaceuticals, Inc | 6 | $114 |
| Janssen Scientific Affairs, LLC | 1 | $93 |
| Shire North American Group Inc | 5 | $82 |
| Madrigal Pharmaceuticals | 4 | $81 |
| Aimmune Therapeutics, Inc. | 3 | $62 |
| Boston Scientific | 1 | $58 |
| Braintree Laboratories, Inc. | 2 | $37 |
| QOL Medical, LLC | 2 | $34 |
| UCB, Inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Cook Medical LLC | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $14 |
| Fresenius Kabi USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$63,487
- IBSRELA$14,673
- Tremfya$499
- Rinvoq$342
- STELARA$258
- REBYOTA$152
- GATTEX$150
- CONMED GENERATORS$128
- CONMED HEMOSTASIS$128
- CONMED BILIARY$128
- OMVOH$124
- VOQUEZNA$108
- Skyrizi$106
How this compares
$88,399 in reported general payments places this provider in the 90th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 16 | $221,108 |
| LinzessLinaclotide | 60 | $55,622 |
| MotegrityPrucalopride Succinate | 26 | $20,677 |
| MovantikNaloxegol Oxalate | 17 | $12,597 |
| Lubiprostone | 53 | $7,845 |
| Mesalamine | 14 | $6,454 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 85 | $5,242 |
| Omeprazole | 278 | $3,973 |
| Famotidine | 216 | $3,565 |
| Colesevelam Hcl | 19 | $2,180 |
| Pantoprazole Sodium | 115 | $2,046 |
| Pyridostigmine Bromide | 22 | $764 |
| Dicyclomine Hcl | 25 | $471 |
| Ondansetron OdtOndansetron | 30 | $458 |
| Budesonide DrBudesonide | 12 | $436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Linzess | $3,621 | $276,73076 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $826 | $20,67726 claims |
| Redhill Biopharma Inc.Movantik | $14 | $12,59717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Houston
- Mazen NoureddinHouston$6.1M
- James MaherHouston$5.3M
- Uma MohanHouston$5M
- John VierlingHouston$2.8M
- Bincy AbrahamHouston$2.5M
- Jason HouHouston$2.3M
- Jignesh ShahHouston$1.7M
- Mouhamad Al-SabbaghHouston$1.6M
- Mohamed OthmanHouston$1.6M
- Harry OjeasHouston$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.